Cryoport, Inc. CYRX
Cryoport, Inc. (Nasdaq: CYRX) is a life-science services company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Recent results and decisions
- Nov 5, 2026approval Cryoport's customer Replimune received accelerated FDA approval for TUDRIQEV for treatment of adults with unresectable advanced cutaneous melanoma.
In Q3 2026, Cryoport's customer, Replimune, received accelerated U.S. Food and Drug Administration (FDA) approval for TUDRIQEV™ for the treatment of adults with unresectable advanced cutaneous melanoma, a skin cancer that has spread too widely or deeply to be safely or completely removed with surger
Filing - Nov 5, 2026approval Crispr Therapeutics and Vertex received FDA supplemental approval to expand CASGEVY label for people 2 years of age and older with SCD or TDT.
Also, during the quarter Crispr Therapeutics and their partner Vertex Pharmaceuticals received FDA supplemental approval to expand the label of CASGEVY® for treatment of people 2 years of age and older with either Sickle Cell Disease (SCD) or Transfusion-dependent Beta Thalassemia (TDT).
Filing - Nov 5, 2026submitted Two of Cryoport's customers filed Biologics License Applications with the FDA in the third quarter.
Two of Cryoport's customers filed Biologics License Applications (BLA) with the FDA in the third quarter and we anticipate another five possible BLA or Marketing Authorization Applications (MAA) in 2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.